Compare · MRK vs PHVS
MRK vs PHVS
Side-by-side comparison of Merck & Company Inc. (MRK) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $385.99B, about 148.8x PHVS ($2.59B).
- MRK has been more active in the news (17 items in the past 4 weeks vs 7 for PHVS).
- MRK has more recent analyst coverage (25 ratings vs 14 for PHVS).
- Company
- Merck & Company Inc.
- Pharvaris N.V.
- Price
- -
- -
- Market cap
- $385.99B
- $2.59B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 17
- 7
- Recent ratings
- 25
- 14
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest MRK
- Merck downgraded by RBC Capital Mkts with a new price target
- Merck upgraded by Morgan Stanley with a new price target
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,350,000 worth of shares (10,000 units at $135.00), decreasing direct ownership by 21% to 36,613 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 54,927 shares at a strike of $109.78 and sold $10,718,495 worth of shares (80,315 units at $133.46), decreasing direct ownership by 36% to 45,509 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)
- Merck upgraded by Daiwa Securities with a new price target
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $788,773 worth of shares (6,050 units at $130.38), decreasing direct ownership by 4% to 155,487 units (SEC Form 4)
- EVP & Pres. MMD Maraldo David R. exercised 18,706 shares at a strike of $82.25 and sold $2,407,797 worth of shares (18,706 units at $128.72) (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 52,847 shares at a strike of $74.49 and sold $6,805,145 worth of shares (52,847 units at $128.77), increasing direct ownership by 0.00% to 31,716 units (SEC Form 4)
Latest PHVS
- Chief Executive Officer Modig Berndt sold $79,686 worth of shares (2,292 units at $34.77) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 130,625 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.
- SEC Form 144 filed by Pharvaris N.V.
- President Lu Peng covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.35% to 65,179 units (SEC Form 4) to satisfy tax liability
- SEC Form 6-K filed by Pharvaris N.V.
- Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
- Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
- Amendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.
- Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
- Chief Executive Officer Modig Berndt sold $80,154 worth of shares (2,292 units at $34.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 132,917 units (SEC Form 4)